Last reviewed · How we verify
NCT03775837
Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults
NA trial testing Panax Ginseng C.A. Mey Extract group in Liver Diseases in 60 participants. Currently enrolling.
30 December 2025
Quick facts
| Lead sponsor | Pusan National University Yangsan Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 December 2018 |
| Primary completion | 30 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Panax Ginseng C.A. Mey Extract group
- Placebo group
Conditions studied
- Liver Diseases — all drugs for Liver Diseases →
Sponsor
Pusan National University Yangsan Hospital
Who can join
Adults 19 to 75, any sex, with Liver Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Panax Ginseng C.A. Mey Extract on liver function in adults for 8 weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy.
Zhu LR, Li SS, Zheng WQ, Ni WJ, et al · · 2023 · cited 41× · PMID 36817459 · DOI 10.3389/fimmu.2023.1086078
Verify or expand the search:
- PubMed search for NCT03775837
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Diseases
Currently open trials in the same condition.
- NCT07400289 — Development of a FibroScan Liver Examination Using a Single Probe · NA · recruiting
- NCT07150624 — The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine · Phase 4 · recruiting
- NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
- NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting
- NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
Other Pusan National University Yangsan Hospital trials
Trials by the same sponsor.
- NCT07511634 — Comparison of Sevoflurane and Desflurane on ANI in Patients Undergoing General Anesthesia: a Prospective Randomized Cont · NA · not yet recruiting
- NCT07324226 — Effects of Combined Heat Application and Acupressure to the Carotid Artery Region on Cerebral Blood Flow in Healthy Adul · NA · recruiting
- NCT07334327 — Extracorporeal Blood Purification Using Oxiris for Septic Shock (EXPLORE Study) · NA · not yet recruiting
- NCT07323823 — The Effect of PBM on the Electrical Activity of the Brain in Stroke Patients · NA · not yet recruiting
- NCT07447271 — Ultrasound Guided Cervical Selective Nerve Root Block Versus Fluoroscopic Guided Cervical Transforaminal Epidural Block · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03775837 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pusan National University Yangsan Hospital
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03775837.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing